NXTC - NextCure, Inc.

12.39
-0.370   -2.986%

Share volume: 80,651
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$12.76
-0.37
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 3%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.04%
1 Month
4.56%
3 Months
9.65%
6 Months
151.83%
1 Year
1,552.00%
2 Year
650.91%
Key data
Stock price
$12.39
P/E Ratio 
N/A
DAY RANGE
$12.04 - $13.45
EPS 
-$18.22
52 WEEK RANGE
$0.22 - $15.74
52 WEEK CHANGE
$1,585.26
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
3.560 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-01-2025
BETA 
1.18
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$43,499
AVERAGE 30 VOLUME 
$40,394
Company detail
CEO: Michael S. Richman
Region: US
Website: nextcure.com
Employees: 90
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

NextCure, Inc. engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. NC410, NC762, NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells.

Recent news